Pharmacovigilance is the study of how a medicine works, how the body responds to it, and the changes that occur over time. Non-clinical pharmacological studies allow scientists to compare a medicine’s beneficial effects with its negative (toxic) effects. This comparison is important so that a thorough benefit-risk analysis can be made before proceeding to test the medicine in clinical (human) studies. If the medicine does proceed to the clinical phase, data gathered during non-clinical pharmacology and toxicology studies help to determine the dosage of medicine given to volunteers in the first clinical studies (first-in-human). Data gathered during pharmacokinetic studies provide information about what happens to a medicine in the body over time. Scientific and mathematical models based on this information help to understand and predict the journey of the medicine and its metabolites through the body. This allows scientists to assess the relationship between the medicine’s beneficial and toxic effects, and to predict the safety/tolerability of the medicine in humans. Data gathered during pharmacokinetic studies are thus essential for determining dosing schedules in clinical trials. The information can be published in our peer reviewed journal with impact factors and are calculated using citations not only from research articles but also review articles (which tend to receive more citations), editorials, letters, meeting abstracts, short communications, and case reports. The inclusion of these publications provides the opportunity for editors and publishers to manipulate the ratio used to calculate the impact factor and try to increase their number rapidly. Impact factor plays a major role for the particular journal. Journal with higher impact factor is considered to be more important than other ones.